Physician profile
Puneet Babbar
NPI 1992776827
$730.14
in general payments reported to CMS, 2019-2025
17 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2022: $72.34 · 2023: $215 · 2024: $184 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $125.00 | 2020 | |
| Lilly USA, LLC | $77.45 | 2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.96 | 2022-2024 | Jardiance |
| Amgen INC. | $45.40 | 2022-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $40.29 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $31.39 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $18.92 | 2024 | |
| Sanofi Pasteur INC. | $17.78 | 2023 | |
| Merck Sharp & Dohme LLC | $17.74 | 2023 | Verquvo, Steglatro |
| Indivior INC. | $16.95 | 2023 | Sublocade |
| Abbvie INC. | $15.24 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2023 | Breztri |
| Alkermes, INC. | $14.46 | 2022 | |
| Glaxosmithkline, LLC. | $14.22 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.82 | 2023 | |
| Athena Bioscience, LLC | $10.28 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Babbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.